-
公开(公告)号：EP3218399A1
公开(公告)日：2017-09-20
申请号：EP15790946.6
申请日：2015-11-06
发明人： BEDOUCHA, Marc , BREUER, Sebastian , DENGL, Stefan , GASSNER, Christian , GEORGES, Guy , GRUENER, Sabine , HARTMANN, Guido , HUELSMANN, Peter Michael , KETTENBERGER, Hubert , MOELLEKEN, Joerg , MOLHOJ, Michael , MUNDIGL, Olaf , REGULA, Joerg Thomas , SCHUMACHER, Ralf , WEISER, Barbara
IPC分类号： C07K16/22
CPC分类号： C07K16/245 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/35 , C07K2317/52 , C07K2317/522 , C07K2317/55 , C07K2317/56 , C07K2317/62 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
摘要翻译： 本文报道了特异性结合选自人ANG2，人VEGF，人IL-1β和人PDGF-B的两种不同抗原的新型双特异性抗体。
-
公开(公告)号：EP2007809A1
公开(公告)日：2008-12-31
申请号：EP07724105.7
申请日：2007-04-10
CPC分类号： C07K16/2863 , C07K16/00 , C07K2317/41 , C07K2317/52
摘要： The invention provides an antibody of human IgGl or IgG3 type being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/ or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.
-
公开(公告)号：EP1836226B1
公开(公告)日：2011-06-22
申请号：EP06706157.2
申请日：2006-01-02
发明人： ENDL, Josef , FUENTES, Maria , GRAUS, Yvo , GROSSMANN, Adelbert , NEUMANN, Sebastian , PARREN, Paul , REBERS, Frank , REGULA, Joerg , SCHUMACHER, Ralf , SEEBER, Stefan , STRACKE, Jan , STUBENRAUCH, Kay-Gunnar , VAN DE WINKEL, Jan , VAN VUGT, Martine , VEREECKEN-VERPLOEGEN, Sandra
IPC分类号： C07K16/28 , A61K39/395 , A61P11/06 , A61P37/08 , C12N15/13 , C12N15/79 , C12N15/70 , C12N5/10 , C12N5/20 , C12N1/21
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/56 , C07K2317/76
摘要： An antibody binding to IL-13Rαl, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
-
4.发明授权
公开(公告)号：EP1646720B1
公开(公告)日：2008-11-05
申请号：EP04763146.0
申请日：2004-07-09
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
IPC分类号： C12N15/13 , C12N5/16 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/2896 , C07K2317/73
-
5.发明公开
公开(公告)号：EP1646720A2
公开(公告)日：2006-04-19
申请号：EP04763146.0
申请日：2004-07-09
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
IPC分类号： C12N15/13 , C12N5/16 , A61K39/395
CPC分类号： C07K16/2863 , A61K2039/505 , C07K16/2896 , C07K2317/73
摘要： An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IGF-IR which is characterized in that said antibody is a) is ofIgG1 isotype, b) shows a ratio of IC50 values of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IG-II to IGF-IR of 1:3 to 3:1, c) inhibits for at least 80% at a concentration of 5 nM IGF-IR phospohrylation in a cellular phosphorylation assay using 3T3 cells providing 400,000 to 600,000 molecules IGF-IR per cell in a medium containing 0.5% heat inactivated fetal calf serum (FCS) when compared to such an assay without said antibody, and d) shows no IGF-IR stimulating activity measured as IGF-IR phophorylation at a concentration of 10 µM in a cellular phosphorylation assay using 3T3 providing 400,000 to 600,000 molecules IGF-IR per cell in a medium containing 0,5% heat inactivated fetal calf serum (FCS) when compared to such an assay without said antibody has improved properties in antitumor therapy.
-
6.发明公开MUTANTS OF IGF BINDING PROTEINS AND METHODS OF PRODUCTION OF ANTAGONISTS THEREOF 审中-公开突变IGF结合蛋白和及其制造方法拮抗剂
公开(公告)号：EP1399475A2
公开(公告)日：2004-03-24
申请号：EP02730290.0
申请日：2002-06-05
发明人： BEISEL, Hans-Georg , DEMUTH, Dirk , ENGH, Richard , HOLAK, Tadeusz , HUBER, Robert , LANG, Kurt , SCHUMACHER, Ralf , ZESLAWSKI, Wojciech
IPC分类号： C07K14/47
CPC分类号： C07K14/65 , A61K38/00 , C07K14/4743 , C07K2299/00
摘要： The present invention provides a crystal suitable for X-ray diffraction, comprising a complex of insulin-like growth factor I or II (IGF) and a polypeptide consisting of the amino acids 39-91 of IGFBP-1, the amino acids 55-107 of IGFBP-2, the amino acids 47-99 of IGFBP-3, the amino acids 39-91 of IGFBP-4, the amino acids 40-92 of IGFBP-5, or the amino acids 40-92 of IGFBP-6 or a fragment thereof consisting at least of the 9?th to 12th¿ cysteine of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, or IGFBP-5 or at least of the 7?th to 10th¿ cysteine of IGFBP-6; methods for the determination of the atomic coordinates of such a crystal; IGFBP mutants with enhanced binding affinity for IGF-I and/or IGF-II, and methods to identify and optimize small molecules which displace IGFs from their binding proteins.
-
公开(公告)号：EP2054086A1
公开(公告)日：2009-05-06
申请号：EP07801642.5
申请日：2007-08-14
发明人： BRANDT, Michael , FISCHER, Stephan , KOPETZKI, Erhard , SANKURATRI, Suryanarayana , SCHUMACHER, Ralf
IPC分类号： A61K47/48
CPC分类号： C07K16/2866 , A61K47/6811 , A61K47/6849 , C07K16/2812 , C07K2317/24 , C07K2317/41 , C12N2740/16033 , C12N2740/16122
摘要： The current invention is related to a conjugate comprising one or more antifusogenic peptides and an antibody against an HIV gp120 binding cell surface receptor, characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of said antibody against an HIV gp120 binding cell surface receptor and to the pharmaceutical use of said conjugate.
-
8.发明公开
公开(公告)号：EP1613658A2
公开(公告)日：2006-01-11
申请号：EP04725024.6
申请日：2004-04-01
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565
摘要： An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IG-RI which is characterized in that said antibody is of human IgG1 isotype, and shows a ratio of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-IR of 1:3 to 3:1, and induces celle death of 20% or more cells of a preparation of IGF-IR expressing cells after 24 hours at a concentration of said antibody of 100 nM by ADCC; has improved properties in antitumor therapy.
-
9.发明授权
公开(公告)号：EP1613658B1
公开(公告)日：2012-03-14
申请号：EP04725024.6
申请日：2004-04-01
发明人： GRAUS, Yvo , KOPETZKI, Erhard , KUENKELE, Klaus-Peter , MUNDIGL, Olaf , PARREN, Paul , REBERS, Frank , SCHUMACHER, Ralf , VAN DE WINKEL, Jan , VAN VUGT, Martine
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565
摘要： An antibody binding to IGF-IR and inhibiting the binding of IGF-I and IGF-II to IG-RI which is characterized in that said antibody is of human IgG1 isotype, and shows a ratio of inhibition of the binding of IGF-I to IGF-IR to the inhibition of binding of IGF-II to IGF-IR of 1:3 to 3:1, and induces celle death of 20% or more cells of a preparation of IGF-IR expressing cells after 24 hours at a concentration of said antibody of 100 nM by ADCC; has improved properties in antitumor therapy.
-
10.发明公开
公开(公告)号：EP2007810A2
公开(公告)日：2008-12-31
申请号：EP07724106.5
申请日：2007-04-10
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/41 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： An antibody binding to IGF-IR, being of human IgG1 or IgG3 type and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/ or the amount of N-terminal alpha-1,3- galactose is 1% or less has improved properties in antitumor therapy.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.02 秒)
